Aegon Funding Company LLC 5.10% Subordinated Notes due 2049 Stock (NYSE: AEFC)

Aegon Funding Company LLC 5.10% Subordinated Notes due 2049 Stock (NYSE:AEFC), Trade Ideas

Aegon Funding Company LLC 5.10% Subordinated Notes due 2049

Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Outperform and lowers the price target from $102 to $95.

News

Price Target

Analyst Ratings

CRSP

Oppenheimer Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $95

WIIM

LPTH

LightPath Technologies shares are trading higher. The company reported Q3 financial results.

JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and lowers the price target from $38 to $34.

JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $34

A worse-than-expected University of Michigan&#8217;s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid<a href="https://www.benzinga.com/markets/equities/24/05/38762249/consumer-sentiment-falls-in-may-inflation-expectations-strongly-exceed-feds-2-goal-they-now-perc"> perceived rising price pressures.</a>
The report disclosed that both near-term and long-term inflation expectations have surged beyond projections this month, causing the broader consumer gauge to hit its lowest levels in six months.
&#8220;If spending slows down and inflation increases, we'll get the opposite of the Goldilocks scenario that many were hoping for, and the Fed will be in an especially difficult position of choosing between accommodating a slowing economy and fighting increasing inflation expectations,&#8221; said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance. 
Echoing this view, Jeffrey Roach, chief economist for LPL Financial, sees rising risks of stagflation, a concern that could unsettle markets. 
At 12:05 p.m. trading in New York, the S&amp;P 500 was 0.1% lower, but it was firmly up by 1.6% for the week, poised to secure a third consecutive week of gains after three of losses.
The Dow Jones Industrial Average was a tad higher, battling to secure the eight straight session of gains, the longest positive streak since December 2023. Tech stocks were flat. Small caps were the underperformers, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) down 0.9%. 
The rising inflation perceptions in the consumer survey rescued the dollar, which eyes a positive weekly close, after two negative ones. 
Treasury yields also inched higher by about 4 basis points across all maturities. The 10-year benchmark hit 4.50%.
Gold surged to $2,385/oz, with the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) up 0.8%. 
The dismal consumer sentiment data sharply weighed on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) with the largest cryptocurrency dropping over 4% from $63,000 to below $60,500 following the report. 
Chart of The Day: Michigan Consumer Sentiment Knocked On Bitcoin 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59-1024x495.png" alt="" class="wp-image-332979" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/10120647/image-59.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,411.32</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,108.22</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,209.09</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>204.04</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m.</figcaption></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was unchanged at $520.20, the SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.2% to $394.65 and the tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.1% to $441.38, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. 
Sector-wise, the Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 0.5%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) was the major laggard, down 0.6%.
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) surged by an astonishing 122%, after the company announced a Covid-19 vaccine licensing deal with Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>). The pharmaceutical company reported a lower than expected loss last quarter, but missed revenue estimates. </li>
<li>MacroGenics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) tumbled by 77% following an interim update on a mid-stage study of a cancer drug candidate, which reported the unfortunate deaths of several study participants. Furthermore, the results for the quarter fell short of expectations.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) rose 0.6% after the company started a tender offer to buy back senior secured notes due 2025 for up to $1.7 billion in cash. </li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) dropped by 4% after the company announced that the FDA won&#8217;t finish its review of MRNA&#8217;s respiratory syncytial virus (RSV) vaccine by the scheduled action date of May 12 due to administrative constraints. The FDA has communicated that it anticipates completing the review by the end of May.</li>
<li>Companies reacting to earnings were Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) up 15%, Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) up 14%, Akamai Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) down 10%, Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) up 8%, DigitalOcean Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) up 6.6%, Construction Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) up 2.6%, Sylvamo Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) down 5%, Costamare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) up 1.3%, Marathon Digital Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) down 8%, Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) down 4%, H&amp;R Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) up 9.7%, and Genpact Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) up 5.7%. </li>
</ul>
Read now: <a href="https://www.benzinga.com/markets/equities/24/05/38764576/tesla-german-gigafactory-faces-climate-protestors-friday-why-are-they-not-jailed-musk-asks">Tesla German Gigafactory Faces Climate Protestors Friday: &#8216;Why Are They Not Jailed,&#8217; Musk Asks</a>
Image generated using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings Beats

Earnings Misses

Equities

Large Cap

Macro Economic Events

Macro Notification

Market Summary

Mid Cap

Bonds

Broad U.S. Equity ETFs

Commodities

Small Cap

Econ #s

Economics

Tech

ETFs

$BTC

ANET

CHTR

CMRE

SPDR Dow Jones Industrial Average ETF Trust

DOCN

MARA

MGNX

MRNA

NVAX

PODD

ROAD

SLVM

XLRE

Select Sector SPDR-Consumer Discretionary

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?

Inflation erodes the purchasing power of money over time, meaning the same amount of money today will buy fewer goods and services down the road. Consequently, saving money without considering investments or strategies to combat inflation could result in diminished value of those savings.
That's one reason real estate mogul<a href="https://www.benzinga.com/personal-finance/24/05/38763051/broke-but-brilliant-grant-cardone-says-necessity-breeds-innovation"> Grant Cardone</a> wrote, "Saving money is for losers" in a<a href="https://twitter.com/GrantCardone/status/1788240819045957840"> May 8 post on X</a>.
Cardone's calculations reveal that if you lived in New York or California in 2020 and had $1 million in a savings account earning 3%, your account would have $1.125 million in it today.
Don't Miss:
<ul>
<li>Only 0.2% of single-family rentals make this platform's rigorous cut. You can co-invest in them <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">with Jeff Bezos and other notable investors for only $100</a>.</li>
<li>Elon Musk, Ken Griffin and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/cityfunds-yield">Investing in its booming real estate market has never been more accessible</a>. </li>
</ul>
But if you deduct the $48,750 you'd owe in federal taxes, $12,500 in state taxes and the $281,250 "inflation effect," your total loss would be $342,500, leaving your account with a real value of $782,500.
That's a loss of 31% of the value of your savings and doesn't account for the<a href="https://www.benzinga.com/real-estate/24/05/38642088/grant-cardone-slams-bidens-tax-proposal-as-another-attempt-to-destroy-middle-class-america"> investment opportunities</a> you missed, Cardone said.
Cardone noted that, "most people's parents instructed them to "save your money," "prepare for a rainy day" and "a penny saved is a penny earned." The math suggests that saving is losing?"
"Money is being printed at record levels, Biden wants to raise taxes, threatening to take capital gains to 44%, Apple makes biggest buyback in history, Mike Saylor…converting his company's fiat to BTC [Bitcoin] and banks are in the headlines everyday for being vulnerable," Cardone wrote in the post. "What your parents told you about saving money might make ‘sense,' but the math proves saving money does not make money."
Trending:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a> </li>
</ul>
The debate over whether to save money or invest it has gained steam since inflation began to soar and the Federal Reserve began hiking interest rates in March 2022. While high interest rates could mean increased returns on savings, experts say there are many things to consider.
"We're now in a position where you can earn decent returns on cash, and actually, now inflation is falling you can earn higher than inflation on chase," Laura Suter, head of personal finance at AJ Bell told CNBC's "Squawk Box Europe."
However, Emma Wall, head of investment analysis and research at Hargreaves Lansdown, talks in favour of Cardone's point of view. She said investing may have a bigger payoff long-term.
"Investing always outperforms cash over the longer time frames," Wall told CNBC. "Over a 30-year time horizon, history suggests that investing can be twice as powerful than leaving your money in cash."
&nbsp;Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. This platform <a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate">allows individuals to invest in commercial real estate with as little as $5,000. </a></li>
<li>This Bezos-backed startup selects America's prime single-family rentals and then <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">lets you invest in them</a> starting from $100. </li>
</ul>

Real Estate

Grant Cardone Says 'Saving Money Is For Losers'

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) with a Market Outperform and maintains $80 price target.

Reiteration

CRNX

JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target

Shares of Diodes Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/DIOD/earnings">quarterly financial results</a>.
Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Diodes shares dipped 9.8% to $68.99 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) gained 40% to $17.06 after the company announced a $120 million registered direct offering and reported Q1 financial results.</li>
<li>AEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares climbed 39.8% to $1.65 after the company disclosed a partnership with LITEON Technology Corporation.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) shares climbed 39.4% to $32.86 after the company reported better-than-expected first-quarter sales results.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) gained 34.3% to $13.90 after the company reported better-than-expected first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) rose 32% to $3.02 following upbeat quarterly results.</li>
<li>Inseego Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) gained 31.4% to $5.05 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) surged 26.3% to $13.99 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Sensus Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) shares rose 22.5% to $4.6699 after the company reported better-than-expected first-quarter financial results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) gained 22.3% to $12.85 after the company reported better-than-expected first-quarter results.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) jumped 21.8% to $1.90 after the company reported better-than-expected quarterly GAAP EPS results.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 21% to $8.39 after the company reported better-than-expected first-quarter financial results and issued strong revenue guidance.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares gained 19.3% to $5.66 in pre-market trading after the company reported better-than-expected first quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) rose 17.2% to $12.79 after the company reported better-than-expected first quarter financial results. The company announced the sale of 100% of its issued and outstanding stock of Interboro Insurance Company to Forza Insurance Holdings.</li>
<li>Global Gas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGAS#NASDAQ">HGAS</a>) rose 15.3% to $1.28.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 15% to $23.42 after the company reported better-than-expected quarterly earnings and authorized a $3 billion share repurchase program.</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) gained 14.6% to $1,478.49 after the company reported better-than-expected first-quarter financial results and issued guidance.</li>
<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) rose 14.4% to $7.61.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) climbed 13.6% to $2.74 following upbeat quarterly results.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 13.2% to $20.19 following second-quarter results.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) rose 11.3% to $106.36 following strong first-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) jumped 11% to $6.50 following first-quarter results.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) gained 8.8% to $9.12 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) jumped 8.7% to $35.68 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $33 to $46.</li>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) gained 7% to $7.30 as the company reported better-than-expected first-quarter earnings and issued strong earnings forecast for the second quarter. The company also appointed Cynthia Williams as its Chief Executive Officer, effective May 20.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) gained 6.8% to $34.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares rose 3.5% to $12.94 after the company reported stronger-than-expected financial results for the first quarter on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares fell 73.4% to $3.9089 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) fell 37.2% to $0.0439 after jumping 20% on Thursday.</li>
<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) dipped 35.8% to $2.9350 after the company reported worse-than-expected quarterly financial results.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) fell 29.3% to $1.30 after the company announced second half and full year 2023 financial results.</li>
<li>Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) fell 29.2% to $2.7290 after the company reported worse-than-expected first-quarter financial results and lowered its FY24 sales guidance below estimates.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) fell 27% to $3.0950 as the company posted a loss for its first quarter on Thursday.</li>
<li>Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) fell 26.6% to $1.16.</li>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) dipped 22.2% to $9.84 following weak quarterly results.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) dipped 22% to $0.25.</li>
<li>The Beauty Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) fell 22% to $2.80 following quarterly results.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) shares fell 21.6% to $1.27 after the company reported worse-than-expected first-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) shares fell 21.5% to $25.51 after the company reported worse-than-expected first-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares declined 20.7% to $0.0579 after the company reported worse-than-expected first quarter financial results.</li>
<li>The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) dipped 19.7% to $3.71 following quarterly results.</li>
<li>CS Disco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) fell 19.6% to $6.50 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) shares fell 18.4% to $0.6937 after jumping around 37% on Thursday.</li>
<li>Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) fell 18.2% to $37.99.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) shares fell 17.7% to $33.43 after the company reported first quarter financial results.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) shares fell 17.3% to $0.7606 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) fell 15.6% to $11.35 following first-quarter financial results.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 14.4% to $0.8320 after the company reported worse-than-expected first quarter GAAP EPS results.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 12.8% to $4.0850 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) declined 12.2% to $14.72.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) fell 11.1% to $21.97 after the company reported second-quarter financial results.</li>
<li>AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) fell 9.5% to $55.08 following first-quarter results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) fell 8.4% to $24.69 after the company reported first-quarter financial results.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) fell 8.1% to $94.16 after the company issued weak guidance.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) declined 7.8% to $17.28 following second-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) dipped 7.4% to $3.3399.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) fell 7% to $39.02.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 5% to $33.13. BMO Capital analyst James Fotheringham maintained Affirm with a Market Perform and lowered the price target from $48 to $46.</li>
<li>Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) shares fell 4.1% to $11.61 as the company priced its secondary offering of 3.75 million common stock by selling stockholder at $11.50 per share.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) shares declined 3.6% to $38.20 after the company reported a first-quarter revenue miss.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38760794/bitcoin-tops-63-000-akash-network-emerges-as-top-gainer">Bitcoin Tops $63,000; Akash Network Emerges As Top Gainer</a>

Intraday Update

Movers

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CDNA

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MLTX

MVIS

NGVC

NTRA

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Northland Capital Markets analyst Ted Jackson downgrades Hyster-Yale Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) from Outperform to Market Perform and raises the price target from $80 to $90.

Downgrades

Northland Capital Markets Downgrades Hyster-Yale Materials to Market Perform, Raises Price Target to $90

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Market Outperform and lowers the price target from $471 to $468.

ARGX

JMP Securities Maintains Market Outperform on argenx, Lowers Price Target to $468

MoffettNathanson analyst Clay Griffin upgrades Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from Sell to Neutral and lowers the price target from $31 to $26.

Upgrades

RBLX

MoffettNathanson Upgrades Roblox to Neutral, Lowers Price Target to $26

Cue Biopharma shares are trading lower. The company reported Q1 financial results.

JMP Securities analyst Constantine Davides reiterates AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) with a Market Outperform and maintains $75 price target.

JMP Securities Reiterates Market Outperform on AMN Healthcare Services, Maintains $75 Price Target

<a href="https://patentcenter.uspto.gov/applications/17273159/ifw/docs">Patent Center (uspto.gov)</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GNOwbQPaIAAMlkw?format=jpg&amp;name=small" alt="Image" /></figure><figure class="image"><img src="https://pbs.twimg.com/media/GNOwbQSacAAiMWx?format=jpg&amp;name=small" alt="Image" /></figure>
&nbsp;

Biotech

General

YTEN

Yield10 Bioscience Has Received A Notice Of Allowance For Its U.S. Patent Application 17/273,159 Titled "Genetically Engineered Land Plants That Express An Increased Seed Yield Protein And/Or An Increased Seed Yield RNA".

Evercore ISI Group analyst Mark Lipacis maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Outperform and raises the price target from $235 to $250.

ONTO

Evercore ISI Group Maintains Outperform on Onto Innovation, Raises Price Target to $250

Deutsche Bank analyst Corinne Blanchard maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Hold and lowers the price target from $75 to $55.

SEDG

Deutsche Bank Maintains Hold on SolarEdge Technologies, Lowers Price Target to $55

EGAN

eGain shares are trading lower after the company reported mixed Q3 financial results.

Mizuho&nbsp;analyst Siti Panigrahi upgraded&nbsp;Squarespace&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) to Buy from Neutral,<a target="_blank" href="https://www.benzinga.com/quote/SQSP/analyst-ratings" rel="noreferrer noopener">&nbsp;raising the forecast to $50 from $34.</a>
According to the analyst, the company can deliver a&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">significant upside to consensus estimates</a>. The upside scenario implies almost 22% year-over-year growth in 2024 (consensus at 19%). Squarespace&nbsp;also has potential for 20% year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">growth in 2025 (consensus at 14%).</a>
The major growth levers underappreciated for Squarespace&nbsp;are &#8211; Google Domains asset acquisition and its halo effect driving new domains, pricing tailwind in 2025, and a modest contribution from Squarespace Payments.&nbsp;
Panigrahi&nbsp;emphasizes that these drivers will position the company for 20%+ growth with 30% uFCF margins over the medium term.
The Google Domains acquisition has already contributed $13 million of revenue in the first quarter alone.
In addition, management noted that Squarespace is seeing &#8220;greatly increased traffic&#8221; in new domains coming onto the platform due to the halo effect from the acquisition, with Google directing users directly to Squarespace for their domain needs, Panigrahi&nbsp;says.
The analyst estimates that the domains could contribute $93 million in revenue in 2024 and $153 million in 2025.
Panigrahi added that a pricing increase for Squarespace could generate a $35 million incremental revenue tailwind in 2025.
Squarespace recognizes payment revenues on a net basis&nbsp;and&nbsp;Payments could generate a modest $6 million revenue contribution in 2025.&nbsp;
The investor day next week could&nbsp;be a catalyst for shares to re-rate, the analyst notes.&nbsp;
After Squarespace&#8217;s first quarter earnings&nbsp;reported&nbsp;earlier this week, the analyst raised FY24 revenue and uFCF estimates to $1.202 billion (19% Y/Y) and $307 million from $1.184 billion (17% Y/Y) and $296 million previously.
Price Action: SQSP shares are trading higher by 3.48% to $38.13 at last check Friday.
Photo via Shutterstock

Analyst Color

Markets

Trading Ideas

SQSP

Squarespace To See Whopping 20% Growth Over Medium Term On Pricing Tailwinds: Analyst

Deutsche Bank analyst Steve Powers maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Hold and raises the price target from $85 to $91.

Deutsche Bank Maintains Hold on Spectrum Brands Holdings, Raises Price Target to $91

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Outperform and lowers the price target from $25 to $24.

JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24

Deutsche Bank analyst Steve Powers maintains Primo Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NYSE">PRMW</a>) with a Hold and raises the price target from $17 to $20.

PRMW

Deutsche Bank Maintains Hold on Primo Water, Raises Price Target to $20

Aegon Funding Company LLC NT 49 goes ex dividend tomorrow

AEFC